NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization49.05 mln
Float8.57 mln
Earnings Date08/13/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
9.98
Transformational upside
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-723
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Actuate Therapeutics is a Fort Worth, Texas-based company focused on developing new cancer treatments. Its main drug, elraglusib, is currently being tested in clinical trials for several difficult-to-treat cancers, including advanced pancreatic cancer and certain childhood cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias. The company was founded in 2015 and has been building its research pipeline with the goal of bringing more effective options to patients with limited treatment choices.
